Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

corporate branding

- PMLiVE

Boehringer eyes obesity market

Aims to widen metabolism portfolio beyond diabetes

- PMLiVE

Boehringer: clinical trial set-up poses challenge in rare diseases

Says more support needed in regulatory process for orphan drugs

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

- PMLiVE

Boehringer files Pradaxa for new VTE indication in Europe

Seeks to add to anticoagulant’s approvals

- PMLiVE

Boehringer says faldaprevir does well in Asian hepatitis C patients

Trial success in patients from Korea, Japan and Taiwan

- PMLiVE

Boehringer invests €35m in research centre in China

Teams up with Shanghai firm to build biopharma facility

- PMLiVE

ASCO: Boehringer’s nintedanib boosts survival in lung cancer subset

Trial date demonstrates benefit in NSCLC patients with adenocarcinomas

- PMLiVE

Boehringer’s Wolfram Carius to step down

He will be replaced by Wolfgang Baiker on the board of managing directors

- PMLiVE

Johnson & Johnson launches first corporate campaign for decade

Campaign intended to reinforce company values to consumer

Boehringer Ingelheim and Lilly launch diabetes education campaign

Follows the partnership’s filing of its SGLT-2 inhibitor for European approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links